Study to Evaluate Methods That Assess the Effect of AZD4017 in Adipose Tissue

AstraZeneca15 enrolled

Overview

The primary purpose of this study is to investigate different methods to evaluate the effect of AZD4017 in adipose tissue after single and multiple doses of AZD4017 in abdominally obese but otherwise healthy subjects.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Masking

SINGLE

Enrollment

Conditions

Obesity

Interventions

AZD4017DRUG

oral suspension, 1200mg, once daily, for 10 days

PlaceboDRUG

Eligibility

Sex: MALEMin age: 18 YearsMax age: 65 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Provision of signed written and dated informed consent * Have a body mass index (BMI) between 27 and 35 kg/m2 * Waist circumference of \>102 cm Exclusion Criteria: * History of any clinical significant disease * Any clinically significant illness, medical/surgical procedure or trauma within 4 weeks of the first administration of investigational product * Any clinically significant abnormalities in clinical chemistry, haematology or urinalysis results as judged by the investigator

Locations (1)

Research Site

Gothenburg, Sweden

Outcomes

Primary Outcomes

To investigate the effect of single and repeated doses of AZD4017 and placebo on mechanisms in adipose tissue involved in metabolic regulation

Time frame: A adipose tissue biospy is taken at baseline, on first day of dosing day, on 4th dosing day and on 9th dosing day.

Secondary Outcomes

Safety and Tolerability (Adverse events, vital signs, ECGs, physical examination, laboratory variables

Time frame: The variables will be measure predose and the repeatedly during the following 10 days after dosing

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.